Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
  • A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/43—Guanidines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers

Definitions

• the present invention relates to mouthwash compositions, in particular compositions comprising the cationic antibacterial agent, chlorhexidine.
• WO 93/16681 discloses oral hygiene compositions including mouthwashes comprising cationic antibacterial agents such as chlorhexidine and as an anti-staining agent polyvinyl pyrrolidone (PVP).
• PVP polyvinyl pyrrolidone
• the present invention provides a mouthwash composition comprising two phases; a first phase comprising chlorhexidine or an orally acceptable acid addition salt thereof and an orally acceptable carrier or excipient and a second phase comprising PVP and an orally acceptable carrier or excipient; the two phases being kept separate until use, whereupon on mixing they provide a single phase having a pH between 6 and 10.
• the pH of the chlorhexidine phase and the PVP phase are such that on mixing they result in a pH from 6.0 to 10.0, preferably 6.0 to 9.0, more preferably 6.0 to 7.0, eg 6.2.
• the initial pH of the chlorhexidine phase is no greater than 6 which has the advantage of increasing the long term storage stability of chlorhexidine.
• the initial pH of the chlorhexidine phase is from 3.0 to 6.0, more preferably 5.0 to 5.9 for example 5.5 to 5.9.
• the pH of the PVP phase is from 6.0 to 10.0, preferably from 6.0 to 9.0, more preferably from 6.0 to 8.0.
• the PVP phase comprises an orally acceptable buffer or pH modifier such that on mixing with the chlorhexidine phase the desired pH is obtained.
• buffers and pH modifiers examples include a base such as sodium hydroxide, or an acid such as acetic, gluconic, tartaric, citric, lactic, or phosphoric acid or a soluble salt thereof. These can be used individually or as mixtures.
• a preferred buffer is sodium acetate.
• the buffer or pH modifier should be present in sufficient quantity to provide the desired buffering effect, suitably from 0.01 to 10%, preferably from 0.1 to 2% by weight of the composition.
• compositions of the present invention can be packaged into a container such as a bottle or tube having two chambers for separating each phase, the container having a dispensing nozzle allowing controlled dispensing and suitably concomitant mixing of said prior phases to use.
• a container such as a bottle or tube having two chambers for separating each phase
• the container having a dispensing nozzle allowing controlled dispensing and suitably concomitant mixing of said prior phases to use.
• compositions can be packaged into a sachet having two chambers separated by a frangible seal which can be ruptured prior to use allowing mixing of the two phases within the sachet.
• Polyvinyl pyrrolidone for use in the present invention suitably has an average molecular weight of at least 5,000 eg in the range 5,000 to 100,000, preferably in the range 5,000 to 50,000.
• Polyvinyl pyrrolidones which have average molecular weights of 10,000, 30,000 and 40,000 are available from Sigma Chemical Co., GAF Corporation and Sigma Chemical Co. respectively.
• Polyvinyl pyrrolidone is suitably present in at least 0.5%, preferably between 0.5 and 30%, more preferably between 0.5 and 25%, and advantageously between 1 and 15% by weight of the composition.
• chlorhexidine or an orally acceptable acid addition salt thereof is present in from 0.005 to 10% preferably 0.01 to 5%, more preferably 0.01 to 2%, by weight of the composition.
• Suitable salts of chlorhexidine include those which have a solubility at 20°C of at least 0.005% w/v and include the digluconate, diformate, diacetate, dipropionate, dihydroiodide, dihydrochloride, dilactate, dinitrate, sulphate, and tartrate. Of these, the digluconate, diacetate and dihydrochloride are favoured.
• the compositions of the present invention may also usefully contain an ionic fluorme-containing compound.
• Suitable ionic fluorine-containing compounds include, for instance, fluoride salts such as amine fluorides and alkali metal fluoride salts, for example sodium fluoride, and monofluorophosphate salts such as alkali metal monofluorophosphate salts, for example sodium monofluorophosphate.
• fluoride salts such as amine fluorides and alkali metal fluoride salts, for example sodium fluoride
• monofluorophosphate salts such as alkali metal monofluorophosphate salts, for example sodium monofluorophosphate.
• the ionic fluorme-containing compound is incorporated into the composition to provide between 50 and 2000ppm, preferably between 100 and 500ppm of fluoride ions.
• compositions of the present invention will suitably comprise as components of the carrier a surfactant and optionally a humectant, preferably in an aqueous or an aqueous/ethanol solution.
• anionic surfactants and anionic humectants should preferably be rejected in favour of non-anionic counterparts such as nonionic, cationic or amphoteric surfactants and nonionic humectants.
• Suitable nonionic surfactants include, for example, polyethoxylated sorbitol esters, in particular polyethoxylated sorbitol monoesters, for instance, PEG(40) sorbitan di-isostearate, and the products marketed under the trade name 'Tween' by ICI; polycondensates of ethylene oxide and propylene oxide (poloxamers), for instance the products marketed under the trade name 'Pluronic' by BASF-Wyandotte; condensates of propylene glycol; polyethoxylated hydrogenated castor oil, for instance, cremophors; and sorbitan fatty esters.
• polyethoxylated sorbitol esters in particular polyethoxylated sorbitol monoesters, for instance, PEG(40) sorbitan di-isostearate, and the products marketed under the trade name 'Tween' by ICI
• Suitable amphoteric surfactants include, for example, long chain imidazoline derivatives such as the product marketed under the trade name 'Miranol C2M' by Miranol; long chain alkyl betaines, such as the product marketed under the tradename ⁇ mpigen BB' by Albright + Wilson, and long chain alkyl amidoalkyl betaines, such as cocamidopropylbetaine, and mixtures thereof.
• Suitable cationic surfactants include the D,L-2-pyrrolidone-5-carboxylic acid salt of ethyl-N-cocoyl-L-arginate, marketed under the trade name CAE by Ajinomoto Co. Inc.
• Preferred surfactants include the nonionic poloxamers and polyethoxylated hydrogenated castor oils.
• the surfactant is present in the range 0.005 to 5%, preferably 0.005 to 1 % , more preferably 0.01 to 0.5 % by weight of the composition.
• Suitable humectants for use in compositions of the invention include for instance glycerin, sorbitol, propylene glycol or polyethylene glycol, or mixtures thereof.
• the humectant may be present in the range from 5 to 70%, preferably 5 to 30%, more preferably 5 to 20% by weight of the composition.
• compositions may be added to the compositions if required, for instance sweetening agents, flavouring agents, colouring agents, preservatives and emulsifiers.
• the PVP phase comprises a sweetening agent such as sodium saccharin which is advantageously kept separate from the chlorhexidine phase thereby preventing unwanted precipitation of a chlorhexidine/saccharin complex on long term storage.
• a sweetening agent such as sodium saccharin
• compositions according to the present invention may be prepared by mixing the ingredients thereof in the required proportions and in any order that is convenient and thereafter and if necessary adjusting the pH to the required value.
• the compositions according to the present invention are of use in reducing or eliminating the stain normally associated with the use of chlorhexidine.
• the present invention provides a mouthwash composition as hereinbefore defined for use in therapy, in particular anti-plaque, anti-caries, anti-calculus and/or periodontal (including anti-gingivitis) therapy.
• Cremophor RH60 is a polyethoxylated hydrogenated castor oil containing on average 60 ethoxy units in the polyethoxylated chain.
• chlorhexidine it is well known in the art that the binding of chlorhexidine to hydroxyapatite is an effective indicator of activity in the oral cavity as chlorhexidine's effectiveness is due to its ability to bind to oral surfaces.
• test method can be used to determine the level of binding of chlorhexidine to hydroxyapatite in vitro :- a)Hydroxyapatite discs of known surface area are soaked overnight in sterile, filtered pooled human saliva at 37 C. b)The discs are then rinsed for 15secounds in 25ml of deionised water. c)Each disc is then treated for 60 seconds by submerging it in 5 ml of the test solution followed by 3 washes for 60 seconds duration in 25ml aliquots of deionised water. d)Bound chlorhexidine is then extracted from the disc and analysed by HPLC.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10806216

Family Applications (1)

Country Status (13)

Cited By (6)

Citations (2)

• 1997
  • 1997-01-18 GB GBGB9701031.8A patent/GB9701031D0/en active Pending
• 1998
  • 1998-01-14 BR BR9806910-1A patent/BR9806910A/pt not_active Application Discontinuation
  • 1998-01-14 CN CN98803284A patent/CN1250368A/zh active Pending
  • 1998-01-14 EP EP98905343A patent/EP1006991A1/en not_active Withdrawn
  • 1998-01-14 CA CA002278237A patent/CA2278237A1/en not_active Abandoned
  • 1998-01-14 EA EA199900547A patent/EA199900547A1/ru unknown
  • 1998-01-14 WO PCT/EP1998/000381 patent/WO1998031332A1/en not_active Application Discontinuation
  • 1998-01-14 JP JP53330398A patent/JP2001508785A/ja active Pending
  • 1998-01-14 AU AU60969/98A patent/AU6096998A/en not_active Abandoned
  • 1998-01-15 ZA ZA98368A patent/ZA98368B/xx unknown
  • 1998-01-16 CO CO98001594A patent/CO4920205A1/es unknown
  • 1998-01-16 AR ARP980100195A patent/AR011535A1/es unknown
  • 1998-01-26 TW TW087101101A patent/TW518232B/zh active

Patent Citations (2)

Also Published As

Similar Documents

Legal Events